These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32923858)

  • 1. Bayesian Approaches to Subgroup Analysis and Related Adaptive Clinical Trial Designs.
    Nugent C; Guo W; Müller P; Ji Y
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32923858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.
    Berry SM; Broglio KR; Groshen S; Berry DA
    Clin Trials; 2013 Oct; 10(5):720-34. PubMed ID: 23983156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian adaptive designs for multi-arm trials: an orthopaedic case study.
    Ryan EG; Lamb SE; Williamson E; Gates S
    Trials; 2020 Jan; 21(1):83. PubMed ID: 31937341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial.
    Ryan EG; Stallard N; Lall R; Ji C; Perkins GD; Gates S
    Trials; 2020 Jan; 21(1):84. PubMed ID: 31937351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example.
    Ryan EG; Bruce J; Metcalfe AJ; Stallard N; Lamb SE; Viele K; Young D; Gates S
    BMC Med Res Methodol; 2019 May; 19(1):99. PubMed ID: 31088354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian Utility-Based Designs for Subgroup-Specific Treatment Comparison and Early-Phase Dose Optimization in Oncology Clinical Trials.
    Thall PF
    JCO Precis Oncol; 2019; 3():. PubMed ID: 33015521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial design with Bayesian adaptive randomization and predictive probability.
    Yin G; Chen N; Lee JJ
    J R Stat Soc Ser C Appl Stat; 2012 Mar; 61(2):219-35. PubMed ID: 24259753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized adaptive enrichment designs.
    Ondra T; Jobjörnsson S; Beckman RA; Burman CF; König F; Stallard N; Posch M
    Stat Methods Med Res; 2019 Jul; 28(7):2096-2111. PubMed ID: 29254436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequentist operating characteristics of Bayesian optimal designs via simulation.
    Zhang Y; Trippa L; Parmigiani G
    Stat Med; 2019 Sep; 38(21):4026-4039. PubMed ID: 31215685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of subpopulations with distinct treatment benefit rate using the Bayesian tree.
    Shen C; Hu Y; Li X; Wang Y; Chen PS; Buxton AE
    Biom J; 2016 Nov; 58(6):1357-1375. PubMed ID: 27356196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimized adaptive enrichment designs for three-arm trials: learning which subpopulations benefit from different treatments.
    Steingrimsson JA; Betz J; Qian T; Rosenblum M
    Biostatistics; 2021 Apr; 22(2):283-297. PubMed ID: 31420983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Signature Enrichment Design with Bayesian Adaptive Randomization.
    Xia F; George SL; Ning J; Li L; Huang X
    J Appl Stat; 2021; 48(6):1091-1110. PubMed ID: 34024982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
    Ryan EG; Brock K; Gates S; Slade D
    BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive Enrichment Designs in Clinical Trials.
    Thall PF
    Annu Rev Stat Appl; 2021 Mar; 8(1):393-411. PubMed ID: 36212769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive designs for subpopulation analysis optimizing utility functions.
    Graf AC; Posch M; Koenig F
    Biom J; 2015 Jan; 57(1):76-89. PubMed ID: 25399844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint.
    Yin G; Chen N; Lee JJ
    Stat Biosci; 2018 Aug; 10(2):420-438. PubMed ID: 30559900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian response-adaptive designs for basket trials.
    Ventz S; Barry WT; Parmigiani G; Trippa L
    Biometrics; 2017 Sep; 73(3):905-915. PubMed ID: 28211944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial.
    Cellamare M; Milstein M; Ventz S; Baudin E; Trippa L; Mitnick CD
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):8-12. PubMed ID: 28240566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bayesian-adaptive decision-theoretic approach can reduce the sample sizes for multiarm exercise oncology trials.
    Buffart LM; Bassi A; Stuiver MM; Aaronson NK; Sonke GS; Berkhof J; van de Ven PM
    J Clin Epidemiol; 2023 Jul; 159():190-198. PubMed ID: 37245703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.